Best Life Sciences Companies in Vienna, Austria
The 105 best Life Sciences companies in Vienna, Austria in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nabriva.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Vienna
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Nabriva Developer of pleuromutilin class of antibiotics for MDR infections | $193M | 90 mo ago | 39 | — | DNNApple iCloud MailYouTube+16 | — | — |
| 2 | HOOKIPA Pharma Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 30 mo ago | 132 | — | DrupalApple iCloud MailMicrosoft 365+19 | — | — |
| 3 | AFFiRiS Developer of therapeutics for neurodegenerative diseases | $83M | 109 mo ago | 10 | Frank Mattner Founder | — | 459 patents Peptide-based therapeutic vaccines targeting neurodegenerative and hypercholesterolemia diseases | — |
| 4 | Themis Bioscience Prophylactic vaccines for infectious diseases | $83M | 81 mo ago | 40 | — | — | 60 patents Recombinant viral vaccine vectors and co‑stimulatory ectodomain proteins for immunomodulation | — |
| 5 | Intercell Developer of vaccines for infectious diseases (merged with Vivalis {France} to form Valneva in 2012) | $79M | 183 mo ago | — | Arunabh Varma Founder & CEO | — | 405 patents Vaccines and immunostimulatory oligodeoxynucleotide formulations targeting bacterial pathogens. | — |
| 6 | Igeneon Cancer Immunotherapy drug discovery company acquired by Aphton in 2004, deadpooled in 2006 | $60M | 268 mo ago | — | — | — | 3 patents Nanoparticle-based vaccine delivery platforms combining antigens, adjuvants, and immunogenic structures. | — |
| 7 | Apeiron Biologics Developer of tumour targeting antibodies and small molecule immunotherapeutics for the treatment of cancer | $30M | 73 mo ago | 14 | — | — | 232 patents Patents concentrated in health & consumer products | — |
| 8 | Ribbon Biolabs Developer of a technology platform for the synthesis of long DNA molecules | $20M | 52 mo ago | 38 | Harold De Vladar Founder and Advisory Board Member | — | 30 patents Enzymatic synthesis and assembly of custom nucleic acid polymers. | 3 launchs |
| 9 | Platomics Marketplace provider for the genomic test-based personalized medicines | $16M | 57 mo ago | 48 | Kriegner Albert CEO | WordPress Block EditorWordPressApple iCloud Mail+28 | — | 1 launch |
| 10 | YGION Developer of immunotherapies for the treatment of cancer | $16M | 25 mo ago | — | Alexander Seitz Co-Founder | — | — | 1 job opening |
| 11 | Flinn AI-enabled solution for manufacturers to automate compliance processes | $11M | 4 mo ago | — | Hasib Samad Co-Founder - Tech | Framer SitesReactCloudflare+19 | — | — |
| 12 | invIOs Developer of immunotherapies for the treatment of cancer | $9M | 20 mo ago | — | Peter Llewellyn-Davies CEO | — | 11 patents Engineered immune cell production and small‑molecule immunomodulators for therapeutic use | — |
| 13 | HeartBeat Developer of stem-cell derived organoid models for cardiac drug discovery | $7M | 31 mo ago | 14 | Michael Krebs Founder & CEO | WebflowApple iCloud MailMicrosoft 365+11 | — | — |
| 14 | Marinomed Developer of drugs for immunology, allergy and infectious diseases | $6M | 56 mo ago | 44 | Eva Prieschl-Grassauer Co-Founder | TYPO3 CMSPHPMicrosoft Advertising+7 | — | 1 launch · 1 partnership |
| 15 | Allcyte Developer of drugs for the treatment of cancer patients | $6M | 62 mo ago | 30 | — | — | — | — |
| 16 | EveliQure Biotechnologies Developing a vaccine against Diarrhea using a proprietary technology platform | $6M | 81 mo ago | 7 | Gabor Somogyi CEO | — | 35 patents High‑dose Shigella vaccine formulation and delivery technologies | — |
| 17 | mySugr Gamification apps for diabetes management and therapy | $5M | 135 mo ago | 130 | — | TurbopackNode.jsTailwind CSS+16 | 27 patents Predictive analytics and risk assessment for blood glucose control in insulin therapy | — |
| 18 | Zytoprotec Develops cytoprotective therapies for the treatment of end-stage renal disease (ESRD) and other diseases | $3M | 89 mo ago | 10 | Christoph Aufricht Co-Founder | — | 34 patents Formulating protective amino‑acid and GSK‑3 inhibitor additives for peritoneal dialysis fluids. | — |
| 19 | a:head bio Developer of therapeutics based on human cerebral organoids for brain disorders | $3M | 79 mo ago | 15 | Oliver Szolar CEO | WordPressMySQLPHP+12 | — | — |
| 20 | HELLO INSIDE Provider of continuous glucose monitoring sensors and related mobile application | $2M | 21 mo ago | 19 | Jürgen Furian Founder | Cart FunctionalityShopifyYouTube+28 | — | — |
| 21 | Nagene Provider of gene synthesis solutions for customized DNA sequences | $2M | 26 mo ago | — | — | — | — | — |
| 22 | PhagoMed Company developing alternatives to antibiotics through their expertise in phage therapy | $2M | 83 mo ago | 14 | Burkhard Wippermann Co-Founder | — | — | — |
| 23 | Panoptes Pharma Small molecule drugs to treat eye diseases | $2M | 127 mo ago | 5 | — | — | 44 patents Ophthalmic drug compounds and albumin-based eye-drop formulations for eye disease treatment | — |
| 24 | Turn-Motion Developer of AI-powered platform for designing and manufacturing custom orthoses | $1M | 15 mo ago | — | Chien-Hua Huang CTO & Co-founder | — | 2 patents Custom 3D‑printed orthopedic orthoses and their manufacturing processes | — |
| 25 | Ivary At-home diagnostic kits to assess the ovarian reserve | $1M | 111 mo ago | — | Silvia Hecher Founder & CEO | — | — | — |
| 26 | Evercyte Cell lines, reagents and research services for pharma and cell therapies | $1M | 45 mo ago | 7 | Otto Kanzler CEO & Co-Founder | Cart FunctionalityWooCommerceWordPress+20 | 14 patents Targeted extracellular vesicle platforms for precision drug delivery | — |
| 27 | TissueGnostics Provider of instruments and software for digital pathology | $984K | 45 mo ago | — | — | JoomlaPHPGSAP+7 | 16 patents Automated histological image analysis and leukocyte segmentation for diagnostic pathology | — |
| 28 | Engenes Developer of recombinant proteins | $773K | 101 mo ago | — | Jens Pontiller Co-Founder | WixSentryBootstrap+15 | — | 2 partnerships |
| 29 | imd Biotech Developer of diagnostic equipment for biomolecule detection and measurement | $431K | 25 mo ago | — | Peter Werzer Co-Founder | — | — | 2 partnerships · 2 awards |
| 30 | TAmiRNA Provider of microRNA-based diagnostics and therapeutics targeting age-associated disorders | $427K | 80 mo ago | 14 | Otto Kanzler CFO and Co-Founder | — | 11 patents Predictive microRNA biomarker signatures for diagnosing liver dysfunction | — |
| 31 | Akribes Biomedical Developing new drugs against chronic wounds using proprietary assays | $295K | 41 mo ago | — | Barbara Wolff-Winiski Co-founder and CEO | — | 35 patents Topical therapies using selective glucocorticoid receptor modulators and PARP inhibitors for chronic skin wound healing | — |
| 32 | ViennaLab Diagnostics Develops membrane-based reverse hybridization tests for DNA variants diagnosis | $113K | 77 mo ago | — | Christian Oberkanins CEO | JoomlaAwesompletePHP+7 | 4 patents Genetic testing probes for diagnosing hereditary hemochromatosis. | — |
| 33 | The Antibody Lab Company developing immunoassays and preclinical biologics through their proprietary antibody engineering and… | $110K | 127 mo ago | — | Gottfried Himmler co-founder | — | 7 patents Lectin-based microbial contamination assays and cardiac NT‑proBNP biomarker diagnostics | — |
Top 12 Life Sciences companies in Vienna
#1
Series A · Vienna, Vienna · founded 2022$11.2Mraised▾
AI-enabled solution for manufacturers to automate compliance processes. It empowers medical device manufacturers to automate compliance processes to launch and operate high-quality products.
- Feb 2026Series A$20M
- Sep 2024Seed$6.7M
- Jul 2023Grant (prize money)$2.2M
- Dec 2022Seed$1.9M
#2
Public · Vienna, Vienna · founded 2011 · 132 employees$133.7Mraised▾
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
- Dec 2023Post IPO$21.2M
- Feb 2019Series D$37.4M
- Dec 2017Series C$59.6M
- Oct 2016Grant (prize money)$4.6M
#3
Series A · Vienna, Vienna · founded 2019$9Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has a proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enabling rapid treatment of patients using their own cells. The lead candidate of the company is APN401 for the treatment of solid tumors. Other drug candidates include INV441 and INV501, an early-stage cell therapy approach to activate tumor-associated immune cells.
- Oct 2024Series A$9M
#4
Funding Raised · Vienna, Vienna · founded 2022$1.3Mraised▾
Developer of AI-powered platform for designing and manufacturing custom orthoses. It provides a system that integrates AI, automation, and fiber technology to produce precision-fit orthotics. The platform captures patient data via an application, uses AI to optimize the structural design, and automates the production process. This enables orthopedic technicians and medical supply stores to streamline orthotic care, reduce manual adjustments, and increase patient throughput. The company's technology facilitates the creation of lighter, biomechanically optimized orthoses that seamlessly integrate with joint systems, enhancing patient mobility and comfort.
- Mar 2025Grant (prize money)$1.3M
#5
Series A · Vienna, Vienna · founded 2022$16.3Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has YGNITE platform that combines next generation sequencing, bioinformatics and the proprietary CARGONAUT vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient.
- May 2024Series A$16.3M
#6
Seed · Vienna, Vienna · founded 2021 · 19 employees$1.8Mraised▾
Provider of continuous glucose monitoring sensors and related mobile application. The company offers tools for individuals to track blood sugar levels and understand metabolic responses. The application provides personalized recommendations based on user data, aiming to promote sustainable lifestyle changes. The offering includes educational programs designed to help users achieve health goals.
- Sep 2024Seed$1.8M
#7
Public · Vienna, Vienna · founded 2006 · 39 employees$193.1Mraised▾
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABP/VABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDA/MAA filing) and pediatric indications (phase I).
- Dec 2018Conventional Debt$25M
- Jul 2018Post IPO$21.3M
- Apr 2015Series B$120M
- Oct 2009PE$22.3M
#8
Acqui-Hired · Vienna, Vienna · founded 2009 · 40 employees$82.5Mraised▾
Themis Bioscience is focussed on developing prophylactic vaccines for infectious diseases. It is using its proprietary Themaxyn platform to identify and advance its vaccine candidates at various stages of development. It has initial vaccine candidates currently in development for chikungunya and dengue fever. The company has developed cancer therapies using a measles vector, such as adding different tumour killing and immune-modulatory payloads to increase the oncolytic effect.
- Sep 2019Series D$44.1M
- Jun 2019Grant (prize money)—
- Jan 2018Series C$12M
- Nov 2016Series B$10.6M
#9
Series B · Vienna, Vienna · founded 2003 · 10 employees$82.6Mraised▾
AFFiRiS is developing the therapeutics for neurodegenerative diseases. The technology called antigen-specific peptide vaccines is used for the prevention and treatment of Parkinson's diseases, Huntington diseases, and multiple system atrophy among others. The company's proprietary AFFITOME Technology delivers peptides that induce an immune response where the generated antibodies target the proteins. Currently, the company has 7 candidates in the clinical pipeline against Parkinson's, MSA and Hypercholesterolemia.
- May 2017Series B$10.9M
- Jun 2016Series B$11.3M
- Jun 2015Series B$11.2M
- Nov 2011Series B$34.4M
#10
Seed · Vienna, Vienna · founded 2021 · 14 employees$6.6Mraised▾
Developer of stem-cell-derived organoid models for cardiac drug discovery. The company has a high-throughput 3D screening platform based on cardiac organoids for cardiovascular drug discovery.
- Nov 2023Seed$4.8M
- May 2021Seed$1.8M
#11
Series A · Vienna, Vienna · founded 2017 · 38 employees$20.1Mraised▾
Developer of a technology platform for the synthesis of long DNA molecules. The company uses genetic solutions by the high-throughput synthesis of DNA. The company is focusing on libraries of DNAs of lengths of up to thousands of base pairs. The company is building genomes, high-throughput libraries, along with providing new products based on DNA, storing data, computing with DNA, and building DNA-based nanotechnological devices.
- Jan 2022Series A$20.1M
- May 2020Grant (prize money)$55.5K
- Dec 2019Grant (prize money)$55.1K
- Mar 2019Seed—
#12
Acquired · Vienna, Vienna · founded 1998$78.6Mraised▾
Intercell was developing vaccines for infectious diseases. It developed antigens and adjuvants for vaccines. In Dec 2012, Vivalis acquired Intercell for $174M, and the combined entity was renamed Valneva. The company had a vaccine for Japanese encephalitis in the market at the time of its acquisition.
- Feb 2011Series B$45M
- Jul 2003Series A$33.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth flat
How research on Biotechnology in Vienna is moving
A read on the academic research around Biotechnology in Vienna — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 49 papers.
Medical University of Vienna and University of Veterinary Medicine Vienna lead Vienna's biotechnology research, focusing on foodborne pathogens and multiple sclerosis, with a cautiously optimistic tone.
- Medical University of Vienna18
- University of Veterinary Medicine Vienna16
- University of Vienna15
- Comprehensive Cancer Center Vienna3
- Vienna Biocenter2
- Intracellular2
- Gene2
- Plectin1
- Cytoskeleton1
- Carcinogenesis1
- Neurodegeneration2
- Reactive oxygen species2
- Endophyte1
- Pigment1
- Aspergillus1
- Food safety2
- Protein C1
- C-Met1
- Text mining1
- MEDLINE1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.